Article
EGFR tyrosine kinase inhibitor (TKI) in patients with advanced non-small cell lung cancer (NSCLC) harboring uncommon EGFR mutations: A real-world study in China.
Lung cancer (Amsterdam, Netherlands) - 1 Jun 2016
Xu Jianlin, Jin Bo, Chu Tianqing, Dong Xue, Yang Haitang, Zhang Yanwei, Wu Dan, Lou Yuqing, Zhang Xueyan, Wang Huiming, Han Baohui
Abstract excerpt
INTRODUCTION: There are a number of uncommon EGFR mutations whose associations with TKIs are not well clarified. Here, we summarize the clinical data of patients with multiple uncommon EGFR mutations and their sensitivity to EGFR TKIs. METHODS: Between January 2009 and September 2014, we retrospectively examined stage IIIB/IV NSCLC patients harboring uncommon mutations in EGFR at the Shanghai Chest Hospital....
Topics
- Adult
- Aged
- Aged, 80 and over
- Carcinoma, Non-Small-Cell Lung
- China
- Disease-Free Survival
- ErbB Receptors
- Female
- Humans
- Lung Neoplasms